# Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

> **NCT01970475** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 526 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** ABP 501
- **BIOLOGICAL:** Adalimumab

## Key facts

- **NCT ID:** NCT01970475
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 526 (ACTUAL)
- **Last updated:** 2016-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01970475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01970475, "Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01970475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*